The suppression of PD-L1/PD-1 interaction using specific inhibitors has shown promising effects in the treatment of several advanced cancers, most notably in melanoma, renal cell carcinoma and non-small cell lung cancer [8-10]. This evidence concerns the gene CD274 and melanoma.